Department of Ophthalmology, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation Services, Bagmati Province, Bhaktapur, Nepal.
Academic and Research Department, BP Eye Foundation, Hospital for Children, Eye, ENT & Rehabilitation, Bagmati Province, Bhaktapur, Nepal.
JNMA J Nepal Med Assoc. 2021 Sep 11;59(241):858-861. doi: 10.31729/jnma.5515.
Intravitreal Bevacizumab injection has now become a routine procedure for retina specialists throughout the world. Easy availability of this monoclonal antibody molecule even in Nepal has brought a revolution in the management of various retinal diseases. This study aims to find out the prevalence of the use of intravitreal Bevacizumab for retinal diseases at the tertiary eye hospital.
This descriptive cross-sectional study was carried out in the retina department at a tertiary care hospital from January 2017 to December 2019 after obtaining ethical clearance from Nepal Health Research Council (Ref: 125/2020P). The sample size was calculated and the study enrolled all patients who received intravitreal Bevacizumab for retinal diseases using convenience sampling technique. Data were analyzed using Statistical Package for Social Science Version 21. Point estimate at 95% Confidence Interval was calculated, along with frequency and percentage for binary data.
Out of 959 total surgical retinal interventions done 296 (30.86%) at 95% Confidence Interval (27.93-33.78) patients received intravitreal Bevacizumab. Out of total intravitreal Bevacizumab injections, 143 (36.7%) injections were given to retinal vein occlusions patients, 127 (32.6%) injections were given to diabetic retinopathy patients and 66 (17%) injections was given to age-related macular degeneration patients. Males 176 (59.5%) outnumbered the females 120 (40.5%) in receiving intravitreal Bevacizumab. Mean baseline Logarithm of the Minimal Angle of Resolution visual acuity, 1.1, improved to, 0.75, after 3 months of intravitreal Bevacizumab.
Intravitreal Bevacizumab was one of the commonest retinal interventions used. Retinal vein occlusion, diabetic retinopathy, and age-related macular degeneration were the commonest retinal diseases needing intravitreal Bevacizumab.
玻璃体内注射贝伐单抗现已成为全球视网膜专家的常规治疗方法。这种单克隆抗体分子在尼泊尔的易得性带来了各种视网膜疾病治疗的革命。本研究旨在了解三级眼科医院视网膜疾病中玻璃体内贝伐单抗的使用情况。
本研究为 2017 年 1 月至 2019 年 12 月在获得尼泊尔健康研究委员会伦理批准（Ref：125/2020P）后，在三级保健医院的视网膜科进行的描述性横断面研究。使用便利抽样技术计算样本量并招募所有接受玻璃体内贝伐单抗治疗视网膜疾病的患者。使用社会科学统计软件包 21 版进行数据分析。计算 95%置信区间的点估计值，以及二元数据的频率和百分比。
在 959 例总手术性视网膜干预中，296 例（95%置信区间为 27.93-33.78）患者接受了玻璃体内贝伐单抗。在总共进行的玻璃体内贝伐单抗注射中，143 次（36.7%）注射用于治疗视网膜静脉阻塞患者，127 次（32.6%）注射用于治疗糖尿病性视网膜病变患者，66 次（17%）注射用于治疗年龄相关性黄斑变性患者。接受玻璃体内贝伐单抗的男性 176 例（59.5%）多于女性 120 例（40.5%）。玻璃体内贝伐单抗治疗 3 个月后，平均基线最小分辨角对数视力从 1.1 提高到 0.75。
玻璃体内贝伐单抗是最常用的视网膜干预措施之一。视网膜静脉阻塞、糖尿病性视网膜病变和年龄相关性黄斑变性是最需要玻璃体内贝伐单抗的常见视网膜疾病。
